ArticleAmerican journal of translational research2025
Serum biomarkers and clinicopathologic postoperative prognostic factors for in endometrial cancer patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the factors influencing the prognosis of endometrial cancer (EC) patients and assess their quality of life.
methodsA retrospective study was conducted involving 190 patients with EC who underwent surgical treatment in the Department of Obstetrics and Gynecology at Beijing Chao-Yang Hospital Affiliated to Capital Medical University between January 2008 and December 2018. Clinical and pathologic data were collected, and all patients received appropriate follow-up. Univariate analysis and Cox proportional hazards regression models were used to identify the factors related to EC prognosis and independent predictors of outcome. Additionally, the predictive performance of the serum biomarkers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and CA199 for patient prognosis were evaluated.
resultsAll 190 EC patients had complete clinical, pathologic, and follow-up data. The median survival time was 88.95 months, with a 5-year survival rate of 94.4%. Univariate analysis showed that older age, postmenopausal status, higher FIGO stage, deeper myometrial invasion, poorer tissue differentiation, lymph node metastasis, and receipt of postoperative chemotherapy and combined radiotherapy were significantly associated with worse prognosis (P<0.05). The sensitivities of CEA, CA125, and CA199 for predicting adverse prognosis were 86.7%, 97.6%, and 82.4%, respectively; specificities were 72.0%, 68.0%, and 80.0%, respectively. The areas under the receiver operating characteristic curves (AUCs) were 0.681, 0.867, and 0.853, respectively.
conclusionPostoperative prognosis in patients with endometrial cancer is influenced by multiple clinical and pathological factors. Serological markers CEA, CA125, and CA199 demonstrated favorable predictive value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.